Grundinformationen
- Standard-SMILES
O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+]- InChIKey
PJAHUDTUZRZBKM-UHFFFAOYSA-K- Summenformel
- C6H7K3O8
- Durchschnittliche Molmasse
- 324,41 g/mol
- Monoisotopische Masse
- 323,9052116
Namen und Bezeichner
- Bevorzugter Name
- Potassium Citrate
- IUPAC
- tripotassium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
6100-05-6、866-84-2- PubChem CID
- 2735208
- DTXSID
DTXSID8042501- ChEMBL
CHEMBL3989822- ChEBI
CHEBI:64746- UNII
- EE90ONI6FF
- EC Number
- 612-062-1、934-739-3
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 142 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 2
- Schwere Atome
- 17
- Formalladung
- 0
- Komplexität
- 211
Experimentelle und physikochemische Eigenschaften
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 100% (181 of 181) of all reports.
Not Classified;Reported as not meeting GHS hazard criteria by 181 of 181 companies. For more detailed information, please visit ECHA C&L website.
Aggregated GHS information provided per 181 reports by companies from 2 notifications to the ECHA C&L Inventory.;Reported as not meeting GHS hazard criteria per 181 of 181 reports by companies.;There are 0 notifications provided by 0 of 181 reports by companies with hazard statement code(s).;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Not Classified;Reported as not meeting GHS hazard criteria by 1 of 1 companies. For more detailed information, please visit ECHA C&L website.
Gefahrenhinweise
Regulatory Information
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate
Tripotassium citrate monohydrate: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and Categories
Not Classified
Not Classified
Sicherheit und Schutzausrüstung
Protective Action Criteria (PAC)
2.1 [mg/m3]
23 [mg/m3]
140 [mg/m3]
2.2 [mg/m3]
24 [mg/m3]
150 [mg/m3]
Toxikologische Informationen
Regulatorische Informationen
Regulatory Information
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate
Tripotassium citrate monohydrate: Does not have an individual approval but may be used under an appropriate group standard
Chemie und Industrie
Pharmakologische Informationen
ATC Code
A - Alimentary tract and metabolism;A12 - Mineral supplements;A12B - Potassium;A12BA - Potassium;A12BA02 - Potassium citrate
QA - Alimentary tract and metabolism;QA12 - Mineral supplements;QA12B - Potassium;QA12BA - Potassium;QA12BA02 - Potassium citrate
Pharmacodynamics
Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.
Mechanism of Action
After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.
FDA Pharmacological Classification
KALI CITRICUM
Calcium Chelating Activity [MoA]; Decreased Coagulation Factor Activity [PE]; Calculi Dissolution Agent [EPC]; Acidifying Activity [MoA]; Anti-coagulant [EPC]
POTASSIUM CITRATE
Calculi Dissolution Agent [EPC]; Calcium Chelating Activity [MoA]; Decreased Coagulation Factor Activity [PE]; Acidifying Activity [MoA]; Anti-coagulant [EPC]
MeSH Pharmacological Classification
Agents that promote the excretion of urine through their effects on kidney function.
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Verwendung und Herstellung
Uses
CIR ingredient: Potassium Citrate
Used in food (sequestrant, emulsifier, and stabilizer) and in medicine as an alkalinizing agent and antiurolithic; [Merck Index] Used as a flavoring agent, nutritional supplement, pH control agent, and sequestrant for foods; [FDA]
Household Products
Information on 2 consumer products that contain Potassium Citrate in the following categories is provided:;• Commercial / Institutional
Information on 29 consumer products that contain Potassium Citrate in the following categories is provided:;• Auto Products;• Commercial / Institutional;• Inside the Home
Use Classification
EPA Safer Chemical Functional Use Classes -> Chelating Agents;Processing Aids and Additives
Safer Chemical Classes -> Green circle - The chemical has been verified to be of low concern
Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
Food Additives -> ACIDITY_REGULATOR; SEQUESTRANT; STABILIZER -> JECFA Functional Classes
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…